Sequencing margins

Pacific Biosciences Inc., slated to go public this week, used its road show to lay out its plans for moving into the black. The third-generation genome sequencing company expects the IPO proceeds, in addition to the $139 million it had in cash at June 30, will get it to profitability.

Pacific Bio hopes to sell 12.5 million shares at $15-$17. At the mid-point, the company would raise $200 million and be valued at $817.8 million...